CXCL10 and kidney disorder: As a further step towards translating our findings into human disease, we examined plasma expression of CXCL10 in patients (n = 37) with CKD stages 3–5, (based on the Kidney Disease Outcomes Quality Initiative guidelines) and compared to healthy controls (n = 24).